Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18906740 | METHOD OF DELIVERY OF DNA OR RNA CARGO USING UNSHIELDED LIPID NANOPARTICLES AND COMPOSITIONS THEREOF | October 2024 | March 2025 | Allow | 5 | 1 | 0 | No | No |
| 18806627 | Technology for improving properties of lipid nanoparticles using lipids in which cis-unsaturated bonds are substiuted with a silicon atom | August 2024 | March 2025 | Allow | 7 | 1 | 0 | No | No |
| 18765624 | Fenugreek Formulation for Lowering Blood Glucose and Weight Loss | July 2024 | February 2025 | Allow | 7 | 1 | 1 | No | No |
| 18718353 | SUPRAMOLECULAR HYDROGEL FOR LIPOPHILIC DRUG DELIVERY, A PREPARATION METHOD THEREFOR, AND USE THEREOF | June 2024 | March 2025 | Allow | 9 | 1 | 0 | No | No |
| 18619103 | Application of AuCs or Substances Containing AuCs in the Preparation of Drugs for Preventing and/or Treating Glaucoma | March 2024 | April 2025 | Allow | 12 | 1 | 0 | No | No |
| 18611735 | NANO LIQUID COMPOSITION CONTAINING CURCUMIN HAVE THE ABILITY TO TREATING BURNS AND INCREASING THE EFFECT OF SCAR HEALING AND METHOD OF MANUFACTURING THE SAME | March 2024 | July 2024 | Allow | 4 | 1 | 0 | No | No |
| 18435999 | 9-(2-HYDROXYQUINOLINE-3-YL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | February 2024 | June 2024 | Allow | 5 | 0 | 0 | No | No |
| 18436000 | 9-(2-HYDROXYQUINOLINE-3-YL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | February 2024 | May 2024 | Allow | 3 | 0 | 0 | No | No |
| 18391712 | INHALABLE COMPOSITIONS FOR USE IN THE TREATMENT OF PULMONARY DISEASES | December 2023 | December 2024 | Allow | 11 | 1 | 0 | No | No |
| 18533497 | NANOEMULSION WITHOUT PROPYLENE GLYCOL | December 2023 | December 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18387525 | 9-(2-HYDROXYQUINOLINE-3-YL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 1 | 1 | No | No |
| 18387296 | IONIZABLE LIPIDS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | November 2023 | June 2025 | Allow | 19 | 1 | 0 | No | No |
| 18490255 | BLENDED FORMULATIONS | October 2023 | February 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18488942 | FORMULATION OF EAR DROPS AND METHODS FOR DELIVERY THEREOF FOR TREATING UPPER RESPIRATORY INFECTIONS | October 2023 | May 2024 | Allow | 7 | 2 | 1 | Yes | No |
| 18372979 | PARENTERAL FORMULATIONS AND USES THEREOF | September 2023 | May 2025 | Allow | 20 | 2 | 1 | No | No |
| 18450414 | NANO LIQUID COMPOSITION CONTAINING CURCUMIN HAVE THE ABILITY TO TREATING BURNS AND INCREASING THE EFFECT OF SCAR HEALING AND METHOD OF MANUFACTURING THE SAME | September 2023 | August 2024 | Abandon | 12 | 2 | 1 | No | No |
| 18460235 | IMMEDIATE RELEASE DOSAGE FORM | September 2023 | January 2025 | Allow | 17 | 1 | 1 | No | No |
| 18457090 | METHOD OF MAKING LIPID-ENCAPSULATED RNA NANOPARTICLES | August 2023 | September 2024 | Allow | 13 | 1 | 0 | No | No |
| 18359271 | COMPOSITIONS COMPRISING N-ACETYL METHYL GABA AND RELATED METHODS | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18358062 | COMPOSITIONS COMPRISING N-ACETYL METHYL GABA AND RELATED METHODS | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18357622 | COMPOSITIONS COMPRISING N-ACETYL METHYL GABA AND RELATED METHODS | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18223205 | ANTI-MICROBIAL SOLUTION FOR SEEDS, CROPS, LIVESTOCK AND PROCESSED FOODS | July 2023 | August 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18350926 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | July 2023 | December 2024 | Allow | 17 | 1 | 0 | No | No |
| 18217172 | Method of Preventing and Treating Chemotherapy-Induced Alopecia | June 2023 | November 2024 | Allow | 17 | 3 | 1 | No | No |
| 18343636 | Atropine Pharmaceutical Compositions | June 2023 | March 2024 | Allow | 8 | 0 | 0 | No | No |
| 18211428 | CHEMOEMBOLIZATION AGENTS | June 2023 | March 2025 | Allow | 21 | 1 | 1 | No | No |
| 18336433 | TREATMENT METHOD FOR TEETH AND GUMS | June 2023 | February 2024 | Allow | 8 | 1 | 0 | No | No |
| 18333375 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR ANOMALIES, NEVUS SEBACEOUS SYNDROME, EPIDERMAL NEVI, AND NEUROFIBROMAS | June 2023 | March 2025 | Allow | 21 | 2 | 0 | No | No |
| 18315011 | SILYL LIPIDS SUITABLE FOR ENHANCED DELIVERY OF ANTI-VIRAL THERAPEUTICS | May 2023 | April 2024 | Allow | 11 | 2 | 1 | No | No |
| 18195330 | TERMITE REPELLANT AND WOOD PROTECTOR AND METHODS | May 2023 | September 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18311616 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | May 2023 | March 2024 | Allow | 11 | 2 | 1 | No | No |
| 18310999 | CAPSULE FOR TREATING ULCERATIVE COLITIS | May 2023 | April 2025 | Allow | 23 | 2 | 0 | No | No |
| 18142532 | SYSTEMS FOR TREATING PULMONARY INFECTIONS | May 2023 | July 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18307718 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS | April 2023 | February 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18138774 | DEODORANT INCLUDING AT LEAST ONE FRUIT ACID AND METHODS OF USING THE SAME | April 2023 | January 2025 | Allow | 21 | 2 | 1 | No | No |
| 18135286 | PURIFICATION OF CLINOPTILOLITE | April 2023 | April 2025 | Allow | 24 | 2 | 1 | No | No |
| 18120770 | LIPOSOMAL FORMULATIONS FOR INHIBITING SARS-CoV-2 REPLICATION AND REDUCING LUNG INFLAMMATION | March 2023 | March 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18117049 | IONIZABLE LIPIDS AND COMPOSITIONS FOR NUCLEIC ACID DELIVERY | March 2023 | August 2023 | Allow | 5 | 0 | 1 | No | No |
| 18173980 | COMPOSITIONS FOR USE IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISORDERS RESULTING FROM CEREBROVASCULAR INJURY | February 2023 | December 2023 | Allow | 10 | 1 | 0 | No | No |
| 18164174 | POLYMER BASED FORMULATION FOR RELEASE OF DRUGS AND BIOACTIVES AT SPECIFIC GIT SITES | February 2023 | April 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18159010 | Lipid nanoparticles containing silyl lipids for use in vaccines and gene therapy | January 2023 | April 2024 | Allow | 14 | 2 | 1 | No | No |
| 18063227 | COMPOSITIONS AND METHODS FOR TREATING PAIN WITH EXTRACELLULAR VESICLES | December 2022 | September 2024 | Allow | 21 | 1 | 0 | No | No |
| 18046719 | PHARMACEUTICAL COMPOSITION COMPRISING STEM CELL-CONDITIONED MEDIUM AND EXOSOME ISOLATED THEREFROM AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF OCULAR DISEASE | October 2022 | January 2024 | Allow | 15 | 2 | 0 | No | No |
| 17965880 | NANOPARTICLE FOR THE REMODELING OF CANCER-ASSOCIATED FIBROBLASTS | October 2022 | March 2025 | Allow | 29 | 1 | 1 | No | No |
| 17960076 | INJECTABLE COMPOSITIONS OF TRITERPENOID ANTIFUNGALS ENCAPSULATED IN LIPOSOMES | October 2022 | May 2024 | Abandon | 20 | 1 | 0 | Yes | No |
| 17952300 | ORAL FILM FORMULATION FOR MODULATING ABSORPTION PROFILE | September 2022 | March 2024 | Allow | 18 | 1 | 0 | No | No |
| 17934873 | BORTEZOMIB COMPOSITIONS | September 2022 | December 2023 | Abandon | 15 | 2 | 1 | No | No |
| 17948184 | MODULATION OF THE NITRIC OXIDE SYNTHASE PATHWAY FOR ORAL HEALTH | September 2022 | November 2023 | Allow | 14 | 1 | 0 | No | No |
| 17930872 | METHODS OF GENERATING CROSS-LINKED PROTEIN FOAMS IN SITU | September 2022 | December 2024 | Allow | 27 | 1 | 1 | No | No |
| 17903989 | TERMITE REPELLENT AND WOOD PROTECTOR | September 2022 | October 2023 | Allow | 14 | 0 | 1 | No | No |
| 17903974 | TERMITE REPELLANT AND WOOD PROTECTOR | September 2022 | October 2023 | Allow | 13 | 0 | 1 | No | No |
| 17892496 | LAYER-BY-LAYER NANOPARTICLES FOR CYTOKINE THERAPY IN CANCER TREATMENT | August 2022 | December 2023 | Allow | 16 | 1 | 0 | No | No |
| 17874890 | CANNABINOID COMPOSITIONS AND METHODS OF USING FOR THE TREATMENT OF NON-EOSINOPHILIC INFLAMMATION AND INFLAMMATORY DISORDERS | July 2022 | September 2023 | Abandon | 13 | 2 | 1 | No | No |
| 17868323 | DELAYED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING VALPROIC ACID, AND USES THEREOF | July 2022 | February 2024 | Allow | 19 | 2 | 0 | No | No |
| 17867235 | MICROPARTICLE FORMULATIONS OF ADENOSINE RECEPTOR ANTAGONISTS FOR TREATING CANCER | July 2022 | October 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17865426 | INHALABLE COMPOSITIONS FOR USE IN THE TREATMENT OF PULMONARY DISEASES | July 2022 | November 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17862635 | NAIL COATING SYSTEM | July 2022 | March 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17809554 | Application of AuCs or Substances Containing AuCs in the Preparation of Drugs for Preventing and/or Treating Glaucoma | June 2022 | February 2024 | Allow | 20 | 1 | 1 | No | No |
| 17832208 | HIGH LIQUIDUS VISCOSITY BIOACTIVE GLASS | June 2022 | January 2024 | Allow | 19 | 1 | 1 | No | No |
| 17735969 | Compositions and Methods for the Removal of Tattoos | May 2022 | October 2024 | Allow | 30 | 1 | 0 | No | No |
| 17724554 | Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery | April 2022 | August 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17719439 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | April 2022 | January 2023 | Allow | 9 | 1 | 0 | No | No |
| 17715625 | SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USE | April 2022 | September 2022 | Allow | 6 | 1 | 1 | No | No |
| 17715619 | SUBSTITUTED PHENYL BORONIC ACID CONTAINING POLYMERS AND METHODS OF USE | April 2022 | September 2022 | Allow | 6 | 1 | 1 | No | No |
| 17705904 | METHOD FOR CONTROLLING DENTAL CARIES AND TREATING TEETH SENSITIVITY | March 2022 | June 2023 | Allow | 14 | 1 | 0 | No | No |
| 17697261 | TREATMENT OF PAIN IN PEDIATRIC PATIENTS BY ADMINISTRATION OF SUSTAINED-RELEASE LIPOSOMAL ANESTHETIC COMPOSITIONS | March 2022 | January 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17675643 | ROOM TEMPERATURE STABLE ORAL CALCITONIN FORMULATION | February 2022 | January 2024 | Allow | 23 | 0 | 0 | No | No |
| 17673315 | SELF-EMULSIONABLE MINERAL OIL AS A VEHICLE IN VACCINES FOR POULTRY | February 2022 | May 2024 | Allow | 27 | 1 | 1 | No | No |
| 17590636 | COMPOSITIONS OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | February 2022 | May 2022 | Allow | 4 | 1 | 1 | No | No |
| 17586228 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS | January 2022 | December 2022 | Abandon | 11 | 2 | 0 | No | No |
| 17581189 | Oral Care Compositions | January 2022 | February 2024 | Allow | 24 | 2 | 0 | No | No |
| 17629236 | PEPTIDE HAVING HAIR GROWTH PROMOTING ACTIVITY AND USE THEREOF | January 2022 | May 2025 | Allow | 40 | 1 | 0 | No | No |
| 17646140 | COMPOSITION FOR PREVENTION OR TREATMENT OF OCULAR DISEASES COMPRISING EXTRACELLULAR VESICLES DERIVED FROM MICROCOCCUS LUTEUS | December 2021 | February 2023 | Allow | 14 | 2 | 1 | No | No |
| 17552487 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | December 2021 | November 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17530245 | TREATMENT OF HEMATOLOGICAL DISORDERS | November 2021 | June 2023 | Abandon | 19 | 2 | 0 | No | No |
| 17512306 | ESSENTIAL OIL EMULSION NOSTRIL TREATMENT COMPOSITION | October 2021 | May 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17505119 | METHOD FOR ADMINISTERING LIPOSOMAL COMPOSITION | October 2021 | April 2022 | Allow | 6 | 1 | 0 | No | No |
| 17503561 | NANO-ARMORED SINGLE CELL PRODUCT FOR TREATING PARKINSON'S DISEASE THROUGH BACTERIA AND A PREPARATION METHOD THEREOF | October 2021 | July 2023 | Allow | 21 | 1 | 0 | No | No |
| 17500491 | METHODS OF LIPID NANOPARTICLE MANUFACTURE AND COMPOSITIONS DERIVED THEREFROM | October 2021 | June 2025 | Allow | 44 | 2 | 0 | No | No |
| 17497503 | Peroxymonosulfate Toothpowder Composition for Tenacious Stains | October 2021 | August 2024 | Allow | 34 | 2 | 1 | No | No |
| 17483129 | Lecithin Vesicles for Oral Delivery | September 2021 | November 2024 | Allow | 38 | 1 | 0 | No | No |
| 17469594 | SPECIALLY FORMULATED COMPOSITIONS OF INHALED NINTEDANIB AND NINTEDANIB SALTS | September 2021 | May 2024 | Allow | 32 | 2 | 0 | No | No |
| 17445577 | INHALABLE POWDER FORMULATIONS OF ALGINATE OLIGOMERS | August 2021 | January 2024 | Allow | 29 | 1 | 0 | No | No |
| 17402998 | INHIBITORS OF INTRACELLULAR INVASION | August 2021 | April 2024 | Allow | 32 | 1 | 1 | No | No |
| 17427999 | BIODEGRADABLE MEMBRANE | August 2021 | May 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17392805 | Electrospun PNIPAAm/PCL Fiber Mats for Aligned Cell Sheets | August 2021 | March 2024 | Allow | 32 | 1 | 1 | No | No |
| 17392405 | PHYTONADIONE COMPOSITIONS AND RELATED METHODS | August 2021 | April 2024 | Allow | 32 | 1 | 1 | No | No |
| 17390514 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | July 2021 | April 2023 | Allow | 20 | 3 | 0 | No | No |
| 17390476 | Dry Powder Treprostinil for the Treatment of Pulmonary Hypertension | July 2021 | April 2023 | Allow | 20 | 3 | 0 | No | No |
| 17425149 | Lecithin Vesicles | July 2021 | January 2025 | Allow | 42 | 2 | 1 | Yes | No |
| 17359414 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS | June 2021 | March 2022 | Allow | 8 | 1 | 0 | No | No |
| 17359411 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS | June 2021 | March 2022 | Allow | 9 | 1 | 1 | No | No |
| 17357651 | SYNERGISTIC COMPOSITION OF VITAMIN C AND VITAMIN K1, AND COMPOSITIONS THEREOF FOR THE TREATMENT OF CANCER | June 2021 | April 2022 | Abandon | 10 | 1 | 0 | No | No |
| 17417171 | CANNABIDIOLOIC ACID ESTERS FOR COSMETIC OR EDIBLE COMPOSITIONS | June 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17309730 | PHARMACEUTICAL COMPOSITION CONTAINING TAMSULOSIN HYDROCHLORIDE WITH EXCELLENT ACID RESISTANCE AND PREPARATION METHOD THEREFOR | June 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17414487 | PROCESS FOR THE MANUFACTURE OF A TABLET OF RIFAXIMIN AND TABLET OF RIFAXIMIN | June 2021 | June 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17340334 | CORE STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF | June 2021 | March 2024 | Allow | 34 | 2 | 1 | No | No |
| 17338658 | TERMITE REPELLANT AND WOOD PROTECTOR | June 2021 | March 2023 | Allow | 21 | 1 | 0 | No | No |
| 17298603 | INHALABLE COMPOSITIONS FOR USE IN THE TREATMENT OF PULMONARY DISEASES | May 2021 | June 2022 | Allow | 12 | 1 | 1 | Yes | No |
| 17324584 | FORMULATIONS FOR TREATING BLADDER CANCER | May 2021 | July 2023 | Abandon | 26 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RONEY, CELESTE A.
With a 15.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner RONEY, CELESTE A works in Art Unit 1612 and has examined 709 patent applications in our dataset. With an allowance rate of 61.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.
Examiner RONEY, CELESTE A's allowance rate of 61.5% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by RONEY, CELESTE A receive 2.54 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by RONEY, CELESTE A is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +22.0% benefit to allowance rate for applications examined by RONEY, CELESTE A. This interview benefit is in the 71% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 19.8% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 33.0% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 45.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 38% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 68.3% of appeals filed. This is in the 49% percentile among all examiners. Of these withdrawals, 63.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 52.9% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.1% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.